Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750486 | 0.87 | KDM4E (0.70) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL954407 | 0.87 | MEN1 (0.90) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL21750482 | 0.87 | KMT2A (0.66) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL21750491 | 0.86 | KMT2A (0.75) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL21750480 | 0.86 | MEN1 (0.93) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL21750478 | 0.85 | KDM4E (0.67) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL6044278 | 0.84 | MEN1 (0.72) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL6043541 | 0.82 | KMT2A (0.70) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL21769224 | 0.82 | MEN1 (0.60) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL21769222 | 0.82 | MEN1 (0.60) | KMT2AMEN1GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | KMT2A 4291/4885MEN1 1178/4885GAA 3887/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | KMT2A 4291/4885MEN1 1178/4885GAA 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.